About Oxford Cancer Analytics
Oxford Cancer Analytics is a Healthcare company based in Oxford (United Kingdom) founded in 2018 by Andreas Halner and Peter Jianrui Liu. Provider of a platform for detection of lung cancer. Oxford Cancer Analytics has raised $16.47 million across 3 funding rounds from investors including Macmillan Cancer Support, Oxford Technology and MEGAROBO. The company has 7 employees. Its chief executive, as recorded, is Peter Jianrui Liu. Oxford Cancer Analytics offers products and services including DEcancer platform. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its legal entity is OXFORD CANCER ANALYTICS LTD. Its competitors include Oncimmune and Inivata; 1 of its 2 listed competitors has raised funding.
Company details
Founded in 2018 in Oxford, United Kingdom, Oxford Cancer Analytics operates in the health technology sector. An AI platform named DEcancer is provided for lung cancer detection through liquid biopsy analysis. Blood test results are examined for DNA, protein, and epigenetics markers. The service supports early identification in clinical settings, with focus on non-invasive diagnostics.
- Total Equity Funding$16.47M (USD)
in 3 rounds
- Latest Funding Round$11M (USD), Series A
Jan 2025
- InvestorsMacmillan Cancer Support
& 12 more
- Employee Count7
Products & Services of Oxford Cancer Analytics
Oxford Cancer Analytics offers a comprehensive portfolio of products and services, including DEcancer platform.
AI-powered platform for detecting cancer biomarkers in blood samples.
Funding Insights of Oxford Cancer Analytics
Oxford Cancer Analytics has successfully raised a total of $16.47M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $11 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $16.47M
- Total Rounds 3
- Last Round Series A — $11M
- First Round $1.77M
(Sep 2021)
- Investors Count 13
All 3 funding rounds of Oxford Cancer Analytics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $11M | Series A | – | We Venture Capital, Cross Border Impact Ventures | |
| Jan 2023 | $3.7M | Seed | – | Eka Ventures | |
| Sep 2021 | $1.77M | Seed | – | – |
13 investors in total: 13 institutional.
Investors in Oxford Cancer Analytics
Oxford Cancer Analytics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Macmillan Cancer Support, Oxford Technology and MEGAROBO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on diagnostics start-ups and digital solutions. | weventurecapital.com | |||
Investments are focused on health technology for global impact. | crossborder.ventures | Toronto, Canada | ||
Venture capital fund focused om consumer tech sector | ekavc.com | London, United Kingdom | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
DigitalDX Ventures is focused on AI and healthcare innovation investments. | digitaldxventures.com | Menlo Park, United States | ||
Early-stage micro-VC investments are focused on UK companies. | 1983 | oxfordtechnology.com | ||
Online cancer support community | 1911 | macmillan.org.uk | London, United Kingdom | |
Medical research and treatments are supported by the community foundation. | 1992 | lifearc.org | London, United Kingdom | |
Robotic solutions for industrial laboratory automation are provided by MEGAROBO. | 2016 | megarobo.com | Singapore, Singapore |
Investor details for Oxford Cancer Analytics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oxford Cancer Analytics
2 people are tracked at Oxford Cancer Analytics (2 in leadership); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Andreas Halner | Co-Founder | Leadership |
Peter Jianrui Liu | Co-Founder & CEO | Leadership |
Complete people profiles for Oxford Cancer Analytics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Oxford Cancer Analytics
3 dated milestones of Oxford Cancer Analytics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Oxford Cancer Analytics is founded.
- Funding First funding round of $1.8M.
- Funding Latest funding round, Series A, of $11.0M.
Competitors of Oxford Cancer Analytics
Oxford Cancer Analytics has 2 listed competitors in our database, 1 of them funded. They include Oncimmune and Inivata.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| oncimmune.com | 2006 | Nottingham, United Kingdom | 52 | Diagnostics and risk assessment solutions for lung cancer are developed. | ||
| inivata.com | 2014 | Cambridge, United Kingdom | $188.79M | 81 | Liquid biopsy platform for cancer detection is developed. |
Detailed competitors of Oxford Cancer Analytics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Oxford Cancer Analytics
The website of Oxford Cancer Analytics (oxcan.org) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 138.7% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oxford Cancer Analytics
Complete news archive for Oxford Cancer Analytics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oxford Cancer Analytics
Oxford Cancer Analytics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Oxford Cancer Analytics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Peter Jianrui Liu is the CEO of Oxford Cancer Analytics, as recorded in our data. They have also founded this company.
Oxford Cancer Analytics is a funded company, having raised a total of $16.47M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.77M, raised on Sep 2021.
Oxford Cancer Analytics has 7 employees.
Founded in 2018 in Oxford, United Kingdom, Oxford Cancer Analytics operates in the health technology sector. An AI platform named DEcancer is provided for lung cancer detection through liquid biopsy analysis. Blood test results are examined for DNA, protein, and epigenetics markers. The service supports early identification in clinical settings, with focus on non-invasive diagnostics.
Oxford Cancer Analytics offers DEcancer platform.
Oxford Cancer Analytics has 13 investors. Key investors include Macmillan Cancer Support, Oxford Technology, MEGAROBO, Cancer Research UK, and The Francis Crick Institute.
Oxford Cancer Analytics operates through Oxford Cancer Analytics Ltd.